EQS Group-Ad-hoc: Medacta Group SA / Key word(s): Sales Result Press Release - 2019 Preliminary unaudited top-line figures Medacta revenue up by 14%, with a strong revenue growth above the market in all regions and business lines "We are pleased with the full year results. We had a positive contribution from all product lines and a balanced geographic growth in all key markets" said Francesco Siccardi, CEO. The Hip line continued to grow and benefit from the AMIS technique, while the integrated proposal of innovative implants, personalised MIKA approach and GMK Single Use Instrumentation sustained the strong Knee performance. The Spine product line showed a nice acceleration in the second part of the year and a good full year performance. The patient-matched and minimally invasive solution, MySpine MIS MC, along with the successful refocus of the structure on the Medacta marketing approach, have been the key elements of this result. In 2019 we completed the launch of our innovative Total Shoulder system, ended in December with the FDA clearance on the My Shoulder. Thanks to our comprehensive product portfolio and to a successful deployment strategy, we were able to achieve a very positive result in this product line as well. Below we show the 2019 sales break-down by product lines:
We had a balanced geographic sales growth in all key markets. Europe registered a good growth, despite price pressure in some of our key countries. The US market realised an overall good performance and remains one of our strategic markets and a key focus for 2020. Asia Pacific delivered a strong result thanks to a fine tuned and well executed marketing strategy, capable to generate noticeable acceleration in the second part of the year. In 2019 Medacta expanded in five new target regions with new distributors worldwide: Cyprus, Ecuador, Lebanon, Paraguay and Tunisia. This expansion in new markets contributed to sustain the acceleration in the RoW area. Below we show the 2019 sales break-down by geographic area:
These preliminary results are unaudited and are based on management's initial analysis of operations for the periods ended December 31, 2019 and are therefore subject to change. The company expects to announce its fourth quarter and audited full year 2019 financial and operating results on April 6th.
Medacta's 2019 Preliminary unaudited top-line figures conference call will take place at 3:00 pm CET today. The event will be webcast live via this link. The audio webcast of the conference call will be available on our website. PIN: 55202794# Contact End of ad hoc announcement |
Language: | English |
Company: | Medacta Group SA |
Strada Regina | |
6874 Castel San Pietro | |
Switzerland | |
Phone: | +41 91 696 6060 |
E-mail: | info@medacta.ch, investor.relations@medacta.ch |
Internet: | www.medacta.com |
ISIN: | CH0468525222 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 957393 |
End of Announcement | EQS Group News Service |
957393 21-Jan-2020 CET/CEST